Laboratory and clinical data | RA patients (n = 59) |
---|---|
Disease duration in days, mean ± SD | 16 ± 11 |
Erosive RA, number (percentage) | 54 (92) |
Positive rheumatoid factor, >10 IU, ELISA, number (percentage) | 52 (88) |
Positive anti-CCP antibodies, >10 IU, ELISA, number (percentage) | 52 (88) |
ESR in mm/hour, mean ± SD; ESR >28, number (percentage) | 28 ± 21; 35 (59) |
CRP in mg/dL, mean ± SD; CRP >15, number (percentage) | 25 ± 41; 23 (39) |
DAS-28, mean ± SD | 4.36 ± 1.7 |
DAS-28 < 2.6, number (percentage) | 11 (19) |
2.6 < DAS-28 < 5.1, number (percentage) | 21 (35) |
DAS-28 > 5.1, number (percentage) | 27 (46) |
Methotrexate, number (percentage) | 49 (83) |
Low dose of prednisone, ≤10 mg/day, number (percentage) | 54 (92) |
Anti-tumor necrosis factor agents, number (percentage) | 11 (17) |
Anti-CD20 agents, number (percentage) | 12 (20) |